They may be particularly effective: (i) in cases where the PRKAA1 or PRKAB2 genes are amplified, causing AMPK over-expression; (ii) when given in combination with genotoxic treatments such as etoposide or radiotherapy, thus reducing the viability of tumour cells during such therapies. This evidence concerns the gene PRKAA1 and neoplasm.